Not China, but Russian Federation announces world's first Covid-19 vaccine
Jul 14 2020
Two groups of volunteers were selected for clinical trials. China's Sinovac Biotech is set to become the third later this month.
In a major breakthrough, Russian Federation has become the first nation to complete clinical trials of COVID-19 vaccine on humans, and the results have proven the medication's effectiveness, the country's media reported on July 12.
Mice injected with the vaccine registered antibody levels of up to 40,960, suggesting that the vaccine's effect decreases as the size of the test subject increases, the researcher added.
There was, on the other hand, no additional data on when this vaccine would enter commercial output phase.
The registry lists the trial as "an open two-stage non-randomised Phase 1 study with the participation of healthy volunteers".
Meanwhile, many countries launched massive efforts to develop a vaccine. The news report said the ministry had claimed that none of the volunteers had reported any complaints, experienced no side-effects, and would be discharged from the hospital soon.
Russian Federation is now working on eight vaccines, according to Sputnik but according to the clinical trials website, 10 vaccine candidates have been listed.
"A vaccine is several years in development", said epidemiologist Arnaud Fontanet, a member of the team of scientists advising the government on the crisis, speaking on French BFM Television.
Vaccine development usually involves a third phase as well.
Sechenov First Moscow State Medical University started conducting the clinical trials on volunteers on June 18. A candidate vaccine is ready to move into industrial production if the last phase provides clear and definitive evidence of its safety and efficacy. The director of the famous Institute for Translational Medicine and Biotechnology, Vadim Tarasov, announced that the first batch of volunteers would be discharged on Wednesday.
"In 2009, Thailand failed to secure swine flu vaccine in time due to the drug's limited production run, even though it was paid for in advance".
Russian Federation has permitted clinical trials of two forms of a potential COVID-19 vaccine developed by the Gamaleya National Epidemiology and Microbiology Research Centre.